(PRWEB) July 10, 2012
The US Drug Watchdog says, "We want to identify any user of the diabetes drug called Actos, if they have developed bladder cancer, and we think we will need the help of family members, and loved ones to get these victims identified. At the same time we intend to make certain every Actos bladder cancer victim has the absolute best attorneys, and or trial law firms working in their behalf." The US Drug Watchdog passionately believes there is no way you could put a price tag on diabetics, who used the diabetes drug called Actos, and then developed bladder cancer. Actos is a member of a class of drugs known as thiazolidinediones, which have been linked to bladder cancer. Actos side effects include increased risk of congestive heart failure, and an increased risk for bladder cancer. The US Drug Watchdog wants to hear from any US diabetic, who used the diabetes drug called Actos, and then developed bladder cancer, or their family members. For more information please call the US Drug Watchdog anytime at 866-714-6466, or contact the group via their web site at http://USDrugWatchdog.Com
The US Drug Watchdog is the premier private pharmaceutical watchdog in the United States. The group says, "Tragically the Internet is loaded with misleading ads about Actos use, and bladder cancer compensation, lawsuits, or class actions. Unfortunately, most of the attorneys or law firms advertising for help with the diabetes drug called Actos, and bladder cancer are middlemen marketing law firms--not the actual trial law firms that will prosecute these cases." They say, "We want to make certain all Actos bladder cancer victims get to the actual trial law firms or attorneys that have the best record in achieving superior results for their clients--period--no middleman marketing law firms, or attorneys." For more information please contact the US Drug Watchdog anytime at 866-714-6466, or contact the group via its web site at http://USDrugWatchdog.com
Case number 11cv2406 BEN BGS in the Federal District Court San Diego, CA.